Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer

Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved overall and progression free survival of patients with metastatic breast cancer, but their effect on short and long-term kidney function is unknown. We found that early, mild estimated glomerular filtration rate (eGFR) decline...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanna, Paul E., Strohbehn, Ian A., Moreno, Daiana, Harden, Destiny, Seethapathy, Rituvanthikaa, Sawtell, Rani, Wang, Qiyu, Ouyang, Tianqi, Katz-Agranov, Nurit, Dinulos, James, Wander, Seth A., Gupta, Shruti, Sise, Meghan E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439887/
https://www.ncbi.nlm.nih.gov/pubmed/37598278
http://dx.doi.org/10.1038/s41523-023-00576-5
_version_ 1785093049083232256
author Hanna, Paul E.
Strohbehn, Ian A.
Moreno, Daiana
Harden, Destiny
Seethapathy, Rituvanthikaa
Sawtell, Rani
Wang, Qiyu
Ouyang, Tianqi
Katz-Agranov, Nurit
Dinulos, James
Wander, Seth A.
Gupta, Shruti
Sise, Meghan E.
author_facet Hanna, Paul E.
Strohbehn, Ian A.
Moreno, Daiana
Harden, Destiny
Seethapathy, Rituvanthikaa
Sawtell, Rani
Wang, Qiyu
Ouyang, Tianqi
Katz-Agranov, Nurit
Dinulos, James
Wander, Seth A.
Gupta, Shruti
Sise, Meghan E.
author_sort Hanna, Paul E.
collection PubMed
description Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved overall and progression free survival of patients with metastatic breast cancer, but their effect on short and long-term kidney function is unknown. We found that early, mild estimated glomerular filtration rate (eGFR) decline was common in patients treated with CDK 4/6 inhibitors; however, severe kidney injury is rare and long-term eGFR decline is uncommon.
format Online
Article
Text
id pubmed-10439887
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-104398872023-08-21 Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer Hanna, Paul E. Strohbehn, Ian A. Moreno, Daiana Harden, Destiny Seethapathy, Rituvanthikaa Sawtell, Rani Wang, Qiyu Ouyang, Tianqi Katz-Agranov, Nurit Dinulos, James Wander, Seth A. Gupta, Shruti Sise, Meghan E. NPJ Breast Cancer Brief Communication Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved overall and progression free survival of patients with metastatic breast cancer, but their effect on short and long-term kidney function is unknown. We found that early, mild estimated glomerular filtration rate (eGFR) decline was common in patients treated with CDK 4/6 inhibitors; however, severe kidney injury is rare and long-term eGFR decline is uncommon. Nature Publishing Group UK 2023-08-19 /pmc/articles/PMC10439887/ /pubmed/37598278 http://dx.doi.org/10.1038/s41523-023-00576-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Brief Communication
Hanna, Paul E.
Strohbehn, Ian A.
Moreno, Daiana
Harden, Destiny
Seethapathy, Rituvanthikaa
Sawtell, Rani
Wang, Qiyu
Ouyang, Tianqi
Katz-Agranov, Nurit
Dinulos, James
Wander, Seth A.
Gupta, Shruti
Sise, Meghan E.
Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
title Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
title_full Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
title_fullStr Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
title_full_unstemmed Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
title_short Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
title_sort adverse kidney outcomes of cdk 4/6 inhibitors for metastatic breast cancer
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439887/
https://www.ncbi.nlm.nih.gov/pubmed/37598278
http://dx.doi.org/10.1038/s41523-023-00576-5
work_keys_str_mv AT hannapaule adversekidneyoutcomesofcdk46inhibitorsformetastaticbreastcancer
AT strohbehniana adversekidneyoutcomesofcdk46inhibitorsformetastaticbreastcancer
AT morenodaiana adversekidneyoutcomesofcdk46inhibitorsformetastaticbreastcancer
AT hardendestiny adversekidneyoutcomesofcdk46inhibitorsformetastaticbreastcancer
AT seethapathyrituvanthikaa adversekidneyoutcomesofcdk46inhibitorsformetastaticbreastcancer
AT sawtellrani adversekidneyoutcomesofcdk46inhibitorsformetastaticbreastcancer
AT wangqiyu adversekidneyoutcomesofcdk46inhibitorsformetastaticbreastcancer
AT ouyangtianqi adversekidneyoutcomesofcdk46inhibitorsformetastaticbreastcancer
AT katzagranovnurit adversekidneyoutcomesofcdk46inhibitorsformetastaticbreastcancer
AT dinulosjames adversekidneyoutcomesofcdk46inhibitorsformetastaticbreastcancer
AT wandersetha adversekidneyoutcomesofcdk46inhibitorsformetastaticbreastcancer
AT guptashruti adversekidneyoutcomesofcdk46inhibitorsformetastaticbreastcancer
AT sisemeghane adversekidneyoutcomesofcdk46inhibitorsformetastaticbreastcancer

Ejemplares similares